LT 002 158
Alternative Names: LT-002-158Latest Information Update: 15 Jan 2024
At a glance
- Originator Shanghai Leadingtac Pharmaceutical
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atopic dermatitis; Hidradenitis suppurativa
Most Recent Events
- 13 Oct 2023 Preclinical trials in Atopic dermatitis in China (PO) (NCT06082323)
- 13 Oct 2023 Preclinical trials in Hidradenitis suppurativa in China (PO) (NCT06082323)
- 13 Oct 2023 Shanghai Leadingtac Pharmaceutical plans a phase I trial for Hidradenitis suppurativa and Atopic dermatitis (In volunteers)in China (PO, Tablet) (NCT06082323)